As it has now for the past 20 months, the COVID-19 pandemic continues to dominate the local, regional, and national landscapes, with the tragic milestone of 700,000 lost lives, ongoing surges across the country, and continued widespread vaccine hesitancy.
However, there is also cause to be hopeful as scientists continue to develop exciting new therapeutics to combat the virus. One such drug is Molnupiravir, an investigational oral antiviral drug discovered by researchers here at Emory, which appears to significantly reduce the risk of hospitalization or death in patients with mild to moderate COVID-19.
Merck and Ridgeback Biotherapeutics are currently advancing the drug after licensing it from Drug Innovation Ventures at Emory (DRIVE). Initially named EIDD-2801, it is the first investigational antiviral that can be administered in pill form, which could ease distribution around the world. Merck has requested Emergency Use Authorization for Molnupiravir from the FDA.
This is a true breakthrough in the fight against COVID-19, and our team at DRIVE, a not-for-profit biotechnology company wholly owned by Emory, has done extraordinary work in bringing this drug to fruition. Congratulations to the DRIVE team and to all the Emory researchers whose work has contributed to this historic discovery and to the renewal of hope in the face of adversity.
Please direct questions and comments to evphafeedback@emory.edu.
Jonathan S. Lewin, MD, FACR Executive Vice President for Health Affairs, Emory University Executive Director, Woodruff Health Sciences Center CEO and Chairman of the Board, Emory Healthcare |